Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial — Meletios A Dimopoulos (2020) | RDL Network
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
Ixazomib maintenance prolongs PFS with no unexpected toxicity in patients with NDMM not undergoing ASCT. To our knowledge, this is the first PI demonstrated in a randomized clinical trial to have single-agent efficacy for maintenance and is the first oral PI option in this patient population.
Meletios A Dimopoulos, Ivan Špıčka, Hang Quach, Albert Oriol, Roman Hájek, Mamta Garg, Meral Beksaç, Sara Bringhen, Eirini Katodritou, Wee Joo Chng, Xavier Leleu, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Alexander Vorog, Richard Labotka, Bingxia Wang, Antonio Palumbo, Sagar Lonial
Wee Joo Chng, Meral Beksaç, Roman Hájek, Katja Weisel, María‐Victoria Mateos, Andrew Spencer, Shinsuke Iida, Danielle de Farias, Richard Labotka, Tomáš Skácel, Antonio Palumbo, Sagar Lonial, Shaji Kumar, Meletios A Dimopoulos
Antonio Palumbo, Gareth J. Morgan, S. Vincent Rajkumar, Sagar Lonial, Wee Joo Chng, Shinsuke Iida, María‐Victoria Mateos, Meral Beksaç, Hartmut Goldschmidt, Richard Labotka, Kaveri Suryanarayan, Alessandra Di Bacco, Eileen Liao, Bingxia Wang, Meletios A Dimopoulos
Sara Bringhen, Luděk Pour, Reuben Benjamin, Sebastian Grosicki, Chang‐Ki Min, Danielle Leão Cordeiro de Farias, Alexander Vorog, Richard Labotka, Bingxia Wang, Dasha Cherepanov, Lauren E. Cain, Sudhakar Manne, S. Vincent Rajkumar, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.